The U.S. Food and Drug Administration (FDA) approved EXPAREL (bupivacaine liposome injectable suspension) on October 22, 2010 [1].
What is EXPAREL used for?
EXPAREL is approved for the management of postoperative pain and is indicated for single-dose infiltration, which provides analgesia (pain relief) that extends into the postoperative period [1]. It is also indicated for injection into the brachial plexus, providing postsurgical anesthesia [1].
How does EXPAREL work?
EXPAREL utilizes proprietary DepoFoam technology, which encapsulates the anesthetic bupivacaine within a lipid-based matrix [2]. This formulation allows for the slow release of bupivacaine over an extended period, providing prolonged pain relief [2].
When does EXPAREL's patent protection expire?
The patent landscape for EXPAREL is complex and involves multiple patents covering its composition, method of use, and manufacturing [3]. According to DrugPatentWatch.com, there are several patents associated with EXPAREL, with expiry dates extending into the future [3]. For instance, U.S. Patent No. 11,534,410, related to methods of treating postoperative pain, is listed with an expiration date of 2035 [3]. However, patent challenges and litigation can impact the actual market exclusivity period [4].
Who makes EXPAREL?
EXPAREL is manufactured by Pacira BioSciences, Inc. [1][2].